Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Cystadenocarcinoma, Serous 1

Interventions

pembrolizumab 304Carboplatin 155Nivolumab 155Cisplatin 140Cyclophosphamide 132Paclitaxel 128Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 91Gemcitabine 87Dexamethasone 85Biopsy 81Ipilimumab 78Doxorubicin 76Docetaxel 75Rituximab 70Etoposide 67atezolizumab 62durvalumab 61Radiation 60Lenalidomide 59Pemetrexed 58Taxes 57Bevacizumab 55Prednisone 55fludarabine 54olaparib 54Vincristine 50Cytarabine 48Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × ribociclib × 1 year × Clear all
NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Thomas Jefferson University

Phase 1/2 Terminated
52 enrolled 31 charts
Genitourinary

Prostatic Neoplasms

NCT02712723 2026-03-11

FELINE

University of Kansas Medical Center

Phase 2 Active not recruiting
121 enrolled 9 charts
Breast

Breast Neoplasms

NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT03822468 2025-10-16

AMALEE

Novartis

Phase 2 Completed
376 enrolled 17 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡